Evolving role of neoadjuvant therapy in rectal cancer

Current Treatment Options in Oncology

Volumn 14, Issue 3, 2013, Pages 350-364

  Schrag, Deborah ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Chemoradiation; Locally advanced rectal cancer; Neoadjuvant chemotherapy; Overtreatment; Total mesorectal excision

Indexed keywords

ACETYLSALICYLIC ACID; BEVACIZUMAB; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; VITAMIN D;

ABDOMINAL SCINTISCANNING; ADJUVANT THERAPY; ARTICLE; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHEMOPROPHYLAXIS; CHEMORADIOTHERAPY; CHEMOSENSITIZATION; COLON CANCER; COLONOSCOPY; COLORECTAL CANCER; COMORBIDITY; CONTINUOUS INFUSION; DIARRHEA; DIET; DIGITAL RECTAL EXAMINATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG WITHDRAWAL; HAND FOOT SYNDROME; HUMAN; LAPAROSCOPIC SURGERY; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); POST TREATMENT SURVIVAL; POSTOPERATIVE RADIOTHERAPY; PREOPERATIVE RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; SMOKING CESSATION; THORAX SCINTISCANNING; TOTAL MESORECTAL EXCISION; TRANSRECTAL ULTRASONOGRAPHY; TUMOR LOCALIZATION; TUMOR REGRESSION; TUMOR VOLUME;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; LEUCOVORIN; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; RECTAL NEOPLASMS;

EID: 84884205609     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-013-0242-8     Document Type: Article

References (37)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 264:1444-50, 1990.
3. National Comprehensive Cancer Network. NCCN guidelines rectal cancer version 4. 2011.
4. Beets-Tan RG, Beets GL, Vliegen RF, et al. Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet. 2001;357:497-504.
5. MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ. 2006;333:779.
6. Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988;80:21-9.
7. Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med. 1985;312:1465-72.
8. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-40.
9. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926-33. This recent report describes the long term outcomes of the German randomized trial comparing pre and postoperative therapy. It confirms the earlier report demonstrating superiority of preoperative treatment in terms of quality of life and local recurrence rate, but not overall survival.
10. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811-20.
11. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215-23.
12. Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012;30:3827-33. This is a recent Australian trial that demonstrated no statistically significant difference between short and long course preoperative radiation for locally advanced rectal cancer. However, non-significant trends favor the long course arm which had a lower rate of local recurrence. This effect was especially pronounced in the subgroup of patients at high risk.
13. Roh MS, Yothers GA, O'Connell MJ, et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol. 2011(suppl 29; abstr 3503). This is the NSABP randomized trial that demonstrates that capecitabine and infusional 5FU are interchangeable and that oxaliplatin does not add incremental value to chemoradiation therapy.
14. Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28:1638-44.
15. Hofheinz R. Proceedings of ASCO Annual Meeting. 2011. Capecitabine versus 5-fluorouracil-based (neo)adjuvant chemoradiotherapy for locally advanced rectal cancer: Long-term results of a randomized, phase III trial. J Clin Oncol. 2011;29(suppl; abstr 3504).
16. Habr-Gama A, Perez RO, Proscurshim I, et al. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome? Int J Radiat Oncol Biol Phys. 2008;71:1181-8.
17. Garcia-Aguilar J, Smith DD, Avila K, et al. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg. 2011;254:97-102.
18. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery-the clue to pelvic recurrence? Br J Surg. 1982;69:613-6.
19. Heald RJ, Moran BJ, Ryall RD, et al. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg. 1998;133:894-9.
20. Schrag D, Panageas KS, Riedel E, et al. Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. Ann Surg. 2002;236:583-92.
21. Jayne DG, Thorpe HC, Copeland J, et al. Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. Br J Surg. 2010;97:1638-45.
22. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114-23.
23. Benson AB, Bekaii-Saab T, Chan E, et al. NCCN clinical practice guidelines in oncology: Rectal cancer. Version 4, 2013. Available at: NCCN.org. Accessed April 15, 2013.
24. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696-704.
25. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-51.
26. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29:11-6.
27. Khrizman P, Niland JC, ter Veer A, et al. Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis. J Clin Oncol. 2013;31:30-8. This study demonstrates that even at specialty cancer centers, many patients do not start or do not complete postoperative adjuvant systemic therapy.
28. Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol. 2006;24:668-74. This is one of the first studies to evaluate neoadjuvant systemic therapy before chemoradiation.
29. Chua YJ, Barbachano Y, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol. 2010;11:241-8.
30. Fernandez-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol. 2010;28:859-65. This is the Spanish study evaluating neoadjuvant systemic therapy and restaging prior to preoperative radiation. It demonstrates favorable results for consolidation of systemic therapy and chemoradiation before surgery.
31. Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer. J Clin Oncol. 2010;28(suppl; abstr 3511):15s. This abstract reports on the single center pilot from Memorial Sloan Kettering selectively omitting chemoradiation for patients with good response to induction FOLFOX.
32. Meyerhardt JA, Heseltine D, Niedzwiecki D, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006;24:3535-41.
33. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst. 2010;102:365-7.
34. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367:1596-606.
35. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302:649-58.
36. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376:1741-50.
37. Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379:1591-601.